Platelet factor 4 and other CXC chemokines support the survival of normal hematopoietic cells and reduce the chemosensitivity of cells to cytotoxic agents

Blood

Volumn 89, Issue 7, 1997, Pages 2328-2335

  Han, Zhong Chao ^a   Lu, Min ^b   Li, Junmin ^b   Defard, Mai ^b   Boval, Bernadette ^b   Schlegel, Nicole ^b   Caen, Jacques P ^b  

^a Institut des Vaisseaux et du Sang   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOTOXIC AGENT; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 8; METHOTREXATE; PROTAMINE SULFATE; THROMBOCYTE FACTOR 4; TRANSFORMING GROWTH FACTOR BETA1; VINCRISTINE;

ARTICLE; BLOOD CELL; CANCER CELL CULTURE; CELL DEATH; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; COLONY FORMATION; CONTROLLED STUDY; FLOW CYTOMETRY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; NITROBLUE TETRAZOLIUM TEST; PRIORITY JOURNAL; UMBILICAL CORD BLOOD;

EID: 0011374053     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.7.2328     Document Type: Article

References (35)

1. Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K: Properties of the novel proinflammatory supergene 'intercrine cytokine family. Annu Rev Immunol 9:617, 1991
2. Baggiolini M, Dewald B, Moser B: Interleukin-8 and related chemotactic cytokines - CXC and CC chemokines. Adv Immunol 55:97, 1994
3. Mantovani A, Sozzani S: Chemokines. Lancet 343:923, 1994
4. Gewirtz AM, Calabretta B, Rucinski B, Niewiarowski S, Xu WY: Inhibition of human megakaryocytopoiesis in vitro by platelet factor 4 (PF4) and a synthetic COOH-terminal PF4 peptide. J Clin Invest 83:1477, 1989
5. Gewirtz AM, Zhang Jin, Ratajczak J, Ratajczak M, Park KS, Li CQ, Yan Z, Poncz M: Chemokine regulation of human megakaryocytopoiesis. Blood 86:2559, 1995
6. Han ZC, Sensèbe L, Abgrall JF, Brière J: Platelet factor 4 inhibits human megakaryocytopoiesis in vitro. Blood 75:1234, 1990
7. Han ZC, Bellucci S, Tenza D, Caen JP: Negative regulation of human megakaryocytopoiesis by human platelet factor 4 and beta thromboglobulin: Comparative analysis in bone marrow cultures from normal individuals and patients with essential thrombocythaemia and immune thrombocytopenic purpura. Br J Haematol 74:395, 1990
8. Han ZC, Bellucci S, Walz A, Baggiolini M, Caen JP: Negative regulation of human megakaryocytopoiesis by human platelet factor 4 (PF4) and connective tissue-activating peptide III (CTAF-III). Int J Cell Clon 8:253, 1990
9. Han ZC, Bellucci S, Bodevin E, Shen ZX, Caen JP: In vivo inhibition of megakaryocyte and platelet production by platelet factor 4 in mice. C R Acad Sci Paris 313:553, 1991
10. Lebeurier I, Basara N, Aidoudi S, Amiral J, Caen JP, Han ZC: Carboxy-terminal peptides (C1-24 and C13-24) but not (C1-13) of platelet factor 4 inhibit murine megakaryocytopoiesis, an activity which is neutralized by heparin. Br J Haematol 92:29, 1996
11. Aidoudi S, Guigon M, Lebeurier I, Caen JP, Han ZC: In vivo effect of platelet factor 4 (PF4) and tetrapeptide AcSDKP on hematopoiesis of mice treated by 5-fluorouracil. Br J Haematol 94:443, 1996
12. + cord blood cells: Comparative studies with transforming growth factor β1. Br J Haematol 93:490, 1996
13. Brandt JE, Bhalla K, Hoffman R: Effect of interleukin-3 and c-kit ligand on the survival of various classes of human hematopoietic progenitor cells. Blood 83:1507, 1994
14. Leary AG, Zeng HQ, Clark SC, Ogawa M: Growth factor requirements for survival in G0 and entry into the cell cycle of primitive human hemopoietic progenitors. Proc Natl Acad Sci USA 89:4013, 1992
15. Amiral J, Bridey F, Wolf M, Boyer-Neumann C, Fressinaud E, Vissac AM, Peynaud-Debayle E, Dreyfus M, Meyer D: Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: A study of 44 cases. Thromb Haemost 73:21, 1995
16. Sargent JM, Taylor CG: Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukemia. Br J Cancer 60:206, 1989
17. Lotem J, Sachs L: Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor β1 and cancer chemotherapy compounds in myeloid leukemia cells. Blood 80:1750, 1992
18. Moore MAS: Clinical implications of positive and negative hematopoietic stem cell regulators. Blood 78:1, 1991
19. Han ZC, Caen JP: Cytokines acting on committed haematopoietic progenitors. Baillieres Clin Haematol 7:65, 1994
20. Keller JR, Jacobsen SEW, Ortiz M, Gooya J, Ruscetti FW: Mast cell growth factor promotes the survival of progenitor cells in the absence of cell division. J Cell Biochem 17B:65, 1993
21. Williams GT, Smith CA, Spooncer E, Dexter TM, Taylor DR: Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature 343:76, 1990
22. Jacobsen FW, Stokke T, Jacobsen SEW: Transforming growth factor-β potently inhibits the viability-promoting activity of stem cell factor and other cytokines and induces apoptosis of primitive murine hematopoietic progenitor cells. Blood 86:2957, 1995
23. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957, 1993
24. Chabner BA, Myers CE: Antitumor antibiotics, in Devita JR, Hellman S, Rosenberg SA (eds): Cancer, Principles and Practice of Oncology. Philadelphia, PA, Lippincott, 1993, p 374
25. Dunlop DJ, Wright EG, Lorimore S, Graham GJ, Holyoake T, Kerr DJ, Wolpe SD, Pragnell LB: Demonstration of stem cell inhibitor and myeloprotective effects of SCI/MIP1α in vivo. Blood 79:2221, 1992
26. Guigon M, Bonnet D: Inhibitory peptides in hematopoiesis. Exp Hematol 23:477, 1995
27. Paukovits WR, Moser MH, Paukovits J: Protection from arabinofuranosylcytosine and n-mustard-induced myelotoxicity using hemoregulatory peptide pGlu-Glu-Asp-Cys-Lys monomer and dimer. Blood 77:1313, 1991
28. Grzegorzewski K, Ruscett FW, Usui N, Damia G, Longo DL, Carlino JA, Keller JR, Wiltrout RH: Recombinant transforming growth factor β1 and β2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin. J Exp Med 180:1047, 1995
29. Fisher DE: Apoptosis in cancer therapy: Crossing the threshold. Cell 78:539, 1994
30. Caen JP, Xi X, Aidoudi S, Fournier S, Schlegel N, Bellucci S, Han ZC: Facteur 4 plaquettaire, inhibiteur réversible de la mégacaryocytopoièse, protecteur des mégacaryocytes au cours de la chimiothérapie. Bull Acad Natl Med 179:1657, 1995
31. Gupta SK, Singh JP: Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression. J Cell Biol 127:1121, 1994
32. Moser B, Schumacher C, von Tscharner V, Clark-Lewis I, Baggiolini M: Neutrophil-activating peptide 2 and gro/melanoma growth - stimulatory activity interact with neutrophil-activating peptide 1/interleukin 8 receptors on human neutrophils. J Biol Chem 266:10666, 1991
33. Horuk R: The interleukin-8-receptor family: From chemokines to malaria. Immunol Today 15:169, 1994
34. Petersen F, Flad H-D, Brandt E: Neutrophil-activating peptides NAP-2 and IL-8 bind to the same sites on neutrophils but interact in different ways. J Immunol 152:2467, 1994
35. Petersen F, Ludwig A, Flad H-D, Brandt E: TNF-α renders human neutrophils responsive to platelet factor 4. J Immunol 156:1954, 1996